

Canada Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-07-01 | 68 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

Canada Cardiovascular Devices Market Analysis

The Canada cardiovascular devices market size reached USD 1.7 billion in 2025 and is expected to climb to USD 2.30 billion by 2030, translating into a 6.22% CAGR across 2025-2030. Growing procedure volumes tied to an aging population, provincial capital spending on cardiac catheterization labs, and the rapid expansion of remote patient monitoring platforms are setting a durable growth foundation for the Canada cardiovascular devices market. Solid gains are occurring even as centralized group purchasing organizations (GPOs) negotiate lower unit prices, forcing manufacturers to prove quantifiable clinical and economic value. Provincial commitments such as Ontario's USD 31 million Windsor cath-lab expansion and Alberta's fast-tracked Red Deer opening are intensifying competition among suppliers vying for procurement lots. Meanwhile, the Medical Device Single Audit Program (MDSAP) is compressing regulatory timelines, although Health Canada approvals for next-generation ablation catheters continue to lag FDA clearances by several months.

Canada Cardiovascular Devices Market Trends and Insights

Aging Population Driving Procedure Volumes

Nineteen percent of Canadians are now 65 or older, a proportion projected to rise steadily through 2030. Seniors account for 27% of diagnosed ischemic heart disease cases, creating sustained demand for advanced stents, valve implants, and monitoring devices. Beyond sheer volume, older patients present higher comorbidity loads, steering hospitals toward minimally invasive

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

approaches that lower perioperative risk. Device makers are therefore prioritizing smaller-profile catheters and AI-assisted imaging that simplify complex anatomies and shorten recovery times. Provincial health ministries increasingly link capital budgets to population-aging metrics, reinforcing the long-term pull on the Canada cardiovascular devices market.

Provincial Funding for New Catheterization & EP Labs

Ontario's USD 31 million Windsor Regional Hospital project will add a second cath table and enable 24-hour service, addressing local wait lists and lifting utilization of coronary guide wires, drug-eluting stents, and hemostasis devices. Alberta's decision to open Red Deer's lab five years early has similar ripple effects, boosting demand for radiopaque contrast, radial access kits, and mapping catheters in the region. Quebec's St. Mary's General Hospital, funded for a third lab, now manages 43% higher patient throughput than comparable facilities, amplifying purchases of ablation consoles and structural heart closure systems. Collectively, these targeted outlays are reshaping procurement schedules and intensifying supplier competition in the Canada cardiovascular devices market.

Provincial GPOs Compress Premium-Device Pricing

Value-oriented tenders from organizations such as HealthPRO and Mohawk MedBuy are generating 8-12% price reductions on premium cardiovascular products. Suppliers must now furnish longitudinal cost-effectiveness data and real-world outcome evidence to secure formulary positions, raising pre-sale investment requirements. Tiered rebate structures tied to readmission metrics are also gaining traction, incentivizing manufacturers to support post-implant remote monitoring and training programs.

Other drivers and restraints analyzed in the detailed report include:

Rapid Uptake of Minimally Invasive Transcatheter Therapies / Elevated Diabetes & Obesity Rates among Indigenous Populations / Health Canada Licence Lag for Next-Gen Ablation Catheters /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Diagnostic and monitoring devices, however, are on course for a 6.98% CAGR, signaling rising preference for preventive and home-based care. Hospitals continue to allocate sizable capital toward transcatheter valves, drug-eluting stents, and mapping catheters, but provincial telehealth funding now channels incremental dollars toward wearable ECG sensors and cloud-connected blood-pressure systems. Hamilton Health Sciences' MyChart Care Companion program illustrates this pivot, enrolling heart-failure patients in continuous symptom tracking that reduced readmissions during 2024 pilots.

Real-world evidence reinforces the economic advantage of early detection. Boston Scientific's mCRM System delivered a 97.5% complication-free rate in Canadian trial sites, bolstering hospital case for adopting leadless pacemaker-S-ICD combinations. Parallel advances in AI interpretation lower clinician workload and accelerate diagnoses, expanding addressable volumes for monitoring devices nationwide. The Canada cardiovascular devices market readily absorbs these innovations, supported by MDSAP-enabled synchronized North American launches.

The Canada Cardiovascular Devices Market Report is Segmented by Product Type (Diagnostic & Monitoring Devices, Therapeutic and Surgical), Application (Coronary Artery Disease, Arrhythmia & Conduction Disorders, and More), End User (Hospitals & Cardiac Centres, Ambulatory Surgical Centres, and More). The Market Forecasts are Provided in Terms of Value (USD), Based On Availability.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

List of Companies Covered in this Report:

Medtronic / Abbott Laboratories / Boston Scientific / Edwards Lifesciences Corp. / Johnson & Johnson (Biosense Webster / Cordis) / Terumo Corp. / GE Healthcare Technologies / Siemens Healthineers / Koninklijke Philips / Stryker / LivaNova / BIOTRONIK / MicroPort / Merit Medical Systems / Cook Group / Cardinal Health / Zimmer Biomet / Opsens Inc. / AngioDynamics / LeMaitre Vascular / Getinge /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /

Table of Contents:

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Aging Population Driving Procedure Volumes Across Provinces

4.2.2 Provincial Funding for New Catheterization & EP Labs (Ontario & Quebec)

4.2.3 Rapid Uptake of Minimally-Invasive Transcatheter Therapies to Cut Surgical Wait-Times

4.2.4 Elevated Diabetes & Obesity Rates among Indigenous/Northern Canadians Accelerating CAD Onset

4.2.5 MDSAP Harmonization Streamlining Device Approvals for Multinationals

4.2.6 Med-tech Clusters in Toronto & Vancouver Fueling Domestic Wearable/Cardiac-AI Innovation

4.3 Market Restraints

4.3.1 Provincial Group Purchasing Organizations (GPOs) Compress Premium-Device Pricing

4.3.2 Health Canada Licence Lag vs. FDA for Next-Gen Ablation Catheters

4.3.3 Rural Dispersion Limiting Access to Advanced Cardiology Centres

4.3.4 Reimbursement Push-back After High-Profile Implant Longevity Recalls

4.4 Value / Supply-Chain Analysis

4.5 Regulatory Landscape

4.6 Technology Outlook

4.7 Porter's Five Forces

4.7.1 Threat of New Entrants

4.7.2 Bargaining Power of Suppliers

4.7.3 Bargaining Power of Buyers

4.7.4 Threat of Substitutes

4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts

5.1 By Product Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.1 Diagnostic & Monitoring Devices
 - 5.1.1.1 ECG Systems
 - 5.1.1.2 Remote Cardiac Monitor
 - 5.1.1.3 Cardiac MRI
 - 5.1.1.4 Cardiac CT
 - 5.1.1.5 Echocardiography / Ultrasound
 - 5.1.1.6 Fractional Flow Reserve (FFR) Systems
- 5.1.2 Therapeutic & Surgical Devices
 - 5.1.2.1 Coronary Stents
 - 5.1.2.1.1 Drug-Eluting Stents
 - 5.1.2.1.2 Bare-Metal Stents
 - 5.1.2.1.3 Bioresorbable Stents
 - 5.1.2.2 Catheters
 - 5.1.2.2.1 PTCA Balloon Catheters
 - 5.1.2.2.2 IVUS/OCT Catheters
 - 5.1.2.3 Cardiac Rhythm Management
 - 5.1.2.3.1 Pacemakers
 - 5.1.2.3.2 Implantable Cardioverter Defibrillators
 - 5.1.2.3.3 Cardiac Resynchronization Therapy Devices
 - 5.1.2.4 Heart Valves
 - 5.1.2.4.1 TAVR/TAVI
 - 5.1.2.4.2 Mechanical Valves
 - 5.1.2.4.3 Tissue/Bioprosthetic Valves
 - 5.1.2.5 Ventricular Assist Devices
 - 5.1.2.6 Artificial Hearts
 - 5.1.2.7 Grafts & Patches
 - 5.1.2.8 Other Cardiovascular Surgical Devices
- 5.2 By Application
 - 5.2.1 Coronary Artery Disease
 - 5.2.2 Arrhythmia & Conduction Disorders
 - 5.2.3 Heart Failure & Cardiomyopathy
 - 5.2.4 Structural & Congenital Heart Defects
 - 5.2.5 Peripheral Vascular Disease
- 5.3 By End User
 - 5.3.1 Hospitals & Cardiac Centres
 - 5.3.2 Ambulatory Surgical Centres
 - 5.3.3 Cardiology/EP Clinics
 - 5.3.4 Home-care & Remote Monitoring Programs

6 Competitive Landscape

- 6.1 Market Concentration
- 6.2 Market Share Analysis
- 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
- 6.3.1 Medtronic plc
- 6.3.2 Abbott Laboratories
- 6.3.3 Boston Scientific Corp.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.4 Edwards Lifesciences Corp.
- 6.3.5 Johnson & Johnson (Biosense Webster / Cordis)
- 6.3.6 Terumo Corp.
- 6.3.7 GE Healthcare Technologies
- 6.3.8 Siemens Healthineers AG
- 6.3.9 Philips Healthcare
- 6.3.10 Stryker Corp.
- 6.3.11 LivaNova PLC
- 6.3.12 Biotronik SE & Co. KG
- 6.3.13 MicroPort Scientific
- 6.3.14 Merit Medical Systems
- 6.3.15 Cook Medical
- 6.3.16 Cardinal Health Inc.
- 6.3.17 Zimmer Biomet Holdings Inc.
- 6.3.18 Opsens Inc.
- 6.3.19 AngioDynamics Inc.
- 6.3.20 LeMaitre Vascular
- 6.3.21 Getinge

7 Market Opportunities & Future Outlook

7.1 White-Space & Unmet-Need Assessment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Canada Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-07-01 | 68 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-27"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

